Drug transporters and cancer treatment
Author Information
Author(s): Clara Lemos, Gerard J. Peters, Geert Jansen
Primary Institution: VU University Medical Center, Amsterdam, The Netherlands
Hypothesis
How does the breast cancer resistance protein (BCRP) affect the efficacy of tyrosine kinase inhibitors in cancer therapy?
Conclusion
BCRP overexpression can lead to multidrug resistance in cancer cells and may reduce the effectiveness of tyrosine kinase inhibitors.
Supporting Evidence
- BCRP is involved in the resistance to a wide range of anticancer agents.
- Overexpression of BCRP can lead to reduced effectiveness of tyrosine kinase inhibitors.
- Different studies show conflicting results regarding BCRP's impact on treatment response.
Takeaway
Some cancer cells can become resistant to treatment because they have special proteins that pump out the medicine before it can work. This study looks at one of those proteins and how it affects cancer drugs.
Methodology
This minireview discusses the role of BCRP in drug resistance and its interactions with various tyrosine kinase inhibitors.
Limitations
The review highlights the complexity of BCRP's role in drug resistance, which may vary across different cancer types and treatment regimens.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website